{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T09:02:31Z","timestamp":1778144551269,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003810","name":"Hospital de Cl\u00ednicas de Porto Alegre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003810","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Braz J Microbiol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s42770-021-00551-x","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T07:08:51Z","timestamp":1625036931000},"page":"1913-1919","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Amikacin for the treatment of carbapenem-resistant Klebsiella pneumoniae infections: clinical efficacy and toxicity"],"prefix":"10.1007","volume":"52","author":[{"given":"Di\u00f3genes","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia Soska","family":"Baldissera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Mathos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre P.","family":"Zavascki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-2613","authenticated-orcid":false,"given":"Maria Helena","family":"Rigatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"551_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/QCO.0000000000000314","volume":"29","author":"M Bassetti","year":"2016","unstructured":"Bassetti M, Peghin M, Pecori D (2016) The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 29:583\u2013594","journal-title":"Curr Opin Infect Dis"},{"key":"551_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","volume":"17","author":"BG Gutierrez","year":"2017","unstructured":"Gutierrez BG, Salamanca E, Cueto M, Hsueh P, Viale P, Pardo JRP (2017) Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 17:726\u2013734","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"551_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijantimicag.2018.10.010","volume":"53","author":"GS Medeiros","year":"2019","unstructured":"Medeiros GS, Rigatto MH, Falci DR, Zavascki AP (2019) Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Int J Antimicrob Agents 53(2):152\u2013157","journal-title":"Int J Antimicrob Agents"},{"key":"551_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/cid\/cis588","volume":"55","author":"M Tumbarello","year":"2012","unstructured":"Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et al (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clinical infect Dis: Off Publ Infect Dis Soc Am 55:943\u2013950","journal-title":"Clinical infect Dis: Off Publ Infect Dis Soc Am"},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/21505594.2016.1221021","volume":"4","author":"EA Neuner","year":"2016","unstructured":"Neuner EA, Gallagher JC (2016) Pharmacodynamic and pharmacokinetic considerations in the treatment of critically III patients infected with carbapenem-resistant Enterobacteriaceae. Virulence 4:440\u2013452. https:\/\/doi.org\/10.1080\/21505594.2016.1221021","journal-title":"Virulence"},{"issue":"6","key":"551_CR6","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/14787210.2017.1316193","volume":"15","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Klee BO, Bulitta JB (2017) Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility. Expert Rev Anti Infect Ther 15(6):519\u2013526","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"551_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1128\/JCM.05247-11","volume":"50","author":"D Girlich","year":"2012","unstructured":"Girlich D, Poirel L, Nordmann P (2012) Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol 50(2):477\u2013479","journal-title":"J Clin Microbiol"},{"key":"551_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.mimet.2017.08.017","volume":"142","author":"D Weiss","year":"2017","unstructured":"Weiss D, Engelmanna I, Brauna SD, Moneckea S, Ehrichta R (2017) A multiplex real-time PCR for the direct, fast, economic and simultaneous detection of the carbapenemase genes blaKPC, blaNDM, blaVIM and blaOXA48. J Microbiol Methods 142:20\u201326","journal-title":"J Microbiol Methods"},{"key":"551_CR9","volume-title":"Performance standards antimicrobial susceptibility testing; twenty-six informational supplement M100S 2018","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute (2018) Performance standards antimicrobial susceptibility testing; twenty-six informational supplement M100S 2018. CLSI, Wayne"},{"key":"551_CR10","doi-asserted-by":"publisher","first-page":"R204","DOI":"10.1186\/cc2872","volume":"8","author":"R Bellomo","year":"2004","unstructured":"Bellomo R, Ronco C, Kellum JA, Metha RL, Palevsky P (2004) Acute dialysis quality initiative workgroup. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second international Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204\u2013R212","journal-title":"Crit Care"},{"issue":"5","key":"551_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383","journal-title":"J Chronic Dis"},{"key":"551_CR12","unstructured":"Gilbert D, Chambers HF, Eliopoulus GM et al (2019) In: Sanford Guide to Antimicrobial Therapy, 490 Edition, ISBN 9788527736084"},{"issue":"5","key":"551_CR13","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1128\/AAC.02638-15","volume":"60","author":"RK Shields","year":"2016","unstructured":"Shields RK, Clancy CJ, Press EG et al (2016) Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 60(5):3187\u20133192. https:\/\/doi.org\/10.1128\/AAC.02638-15","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"551_CR14","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1093\/jac\/dkw296","volume":"71","author":"LZ Ong","year":"2016","unstructured":"Ong LZ, Tambyah PA, Lum LH et al (2016) Aminoglycoside-associated acute kidney injury in elderly patients with and without shock. J Antimicrob Chemother 71(11):3250\u20133257","journal-title":"J Antimicrob Chemother"},{"key":"551_CR15","doi-asserted-by":"publisher","first-page":"179.e1","DOI":"10.1016\/j.cmi.2014.07.010","volume":"21","author":"MS De Oliveira","year":"2015","unstructured":"De Oliveira MS, de Assis DB, Freire MP et al (2015) Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect 21:179.e1-179.e7","journal-title":"Clin Microbiol Infect"},{"key":"551_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000440867","volume":"131","author":"F Paquette","year":"2015","unstructured":"Paquette F, Jean AB, Brunette V, Ammann H, Lavergne V, Pichette V et al (2015) Acute kidney injury and renal recovery with the use of aminoglycosides: a large retrospective study. Nephron 131:153\u2013160","journal-title":"Nephron"},{"issue":"1","key":"551_CR17","first-page":"27","volume":"17","author":"SK Swan","year":"1997","unstructured":"Swan SK (1997) Aminoglycoside nephrotoxicity. Semin Nephrol 17(1):27\u201333","journal-title":"Semin Nephrol"},{"key":"551_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/cid\/ciu213","volume":"59","author":"RL Nation","year":"2014","unstructured":"Nation RL, Velkov T, Li J (2014) Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clinical Infect Dis: Off Publ Infect Dis Soc Am 59:88\u201394","journal-title":"Clinical Infect Dis: Off Publ Infect Dis Soc Am"},{"issue":"4","key":"551_CR19","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/AAC.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV et al (2016) Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60(4):2443\u20139","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"551_CR20","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-16","volume":"61","author":"AP Zavascki","year":"2017","unstructured":"Zavascki AP, Nation R (2017) Nephrotoxicity of polymyxins: is there any difference between colistimethate and polymyxin B? Antimicrob Agents Chemother 61(3):e02319-16. https:\/\/doi.org\/10.1128\/AAC.02319-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"551_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10096-019-03468-4","volume":"38","author":"MP Freire","year":"2019","unstructured":"Freire MP, Garcia DO, Cury AP, Francisco GR, Santos NF, Spad\u00e3o F et al (2019) The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin and carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 38(4):755\u2013765","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"551_CR22","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1128\/AAC.00387-11","volume":"55","author":"MJ Satlin","year":"2011","unstructured":"Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP (2011) Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55(12):5893\u20135899","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Brazilian Journal of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42770-021-00551-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42770-021-00551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T02:06:16Z","timestamp":1636509976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42770-021-00551-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s42770-021-00551-x","relation":{},"ISSN":["1517-8382","1678-4405"],"issn-type":[{"value":"1517-8382","type":"print"},{"value":"1678-4405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The project was carried out after its approval by the institution\u2019s Research Ethics Committee number 2.687.149 and 2.476.428.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a retrospective study, the ethics committee waived the need for informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors agree on the publication of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alexandre P Zavascki receives research grants from Pfizer. The other authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}